156 related articles for article (PubMed ID: 36628952)
1. Pharmacogenetics of anxiety and depression in Alzheimer's disease.
Cacabelos R; Carril JC; Corzo L; Pego R; Cacabelos N; Alcaraz M; Muñiz A; Martínez-Iglesias O; Naidoo V
Pharmacogenomics; 2023 Jan; 24(1):27-57. PubMed ID: 36628952
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics of Alzheimer's Disease: Novel Strategies for Drug Utilization and Development.
Cacabelos R; Naidoo V; Martínez-Iglesias O; Corzo L; Cacabelos N; Pego R; Carril JC
Methods Mol Biol; 2022; 2547():275-387. PubMed ID: 36068470
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics and therapeutic prospects in dementia.
Cacabelos R
Eur Arch Psychiatry Clin Neurosci; 2008 Mar; 258 Suppl 1():28-47. PubMed ID: 18344047
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
Cacabelos R
Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
[TBL] [Abstract][Full Text] [Related]
5. Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics.
Cacabelos R; Carrera I; Martínez O; Alejo R; Fernández-Novoa L; Cacabelos P; Corzo L; Rodríguez S; Alcaraz M; Nebril L; Tellado I; Cacabelos N; Pego R; Naidoo V; Carril JC
Med Res Rev; 2021 Sep; 41(5):2841-2886. PubMed ID: 34106485
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics.
Cacabelos R; Llovo R; Fraile C; Fernández-Novoa L
Curr Alzheimer Res; 2007 Sep; 4(4):479-500. PubMed ID: 17908053
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.
Cacabelos R
Mol Diagn Ther; 2007; 11(6):385-405. PubMed ID: 18078356
[TBL] [Abstract][Full Text] [Related]
9. Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.
Altar CA; Carhart JM; Allen JD; Hall-Flavin DK; Dechairo BM; Winner JG
Pharmacogenomics J; 2015 Oct; 15(5):443-51. PubMed ID: 25686762
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic considerations in the treatment of Alzheimer's disease.
Cacabelos R; Torrellas C; Teijido O; Carril JC
Pharmacogenomics; 2016 Jun; 17(9):1041-74. PubMed ID: 27291247
[TBL] [Abstract][Full Text] [Related]
11. Targeted Genotyping in Clinical Pharmacogenomics: What Is Missing?
Lopes JL; Harris K; Karow MB; Peterson SE; Kluge ML; Kotzer KE; Lopes GS; Larson NB; Bielinski SJ; Scherer SE; Wang L; Weinshilboum RM; Black JL; Moyer AM
J Mol Diagn; 2022 Mar; 24(3):253-261. PubMed ID: 35041929
[TBL] [Abstract][Full Text] [Related]
12. Phenotype prediction and characterization of 25 pharmacogenes in Thais from whole genome sequencing for clinical implementation.
Mauleekoonphairoj J; Chamnanphon M; Khongphatthanayothin A; Sutjaporn B; Wandee P; Poovorawan Y; Nademanee K; Pongpanich M; Chariyavilaskul P
Sci Rep; 2020 Nov; 10(1):18969. PubMed ID: 33144648
[TBL] [Abstract][Full Text] [Related]
13. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.
Choi HY; Bae KS; Cho SH; Ghim JL; Choe S; Jung JA; Jin SJ; Kim HS; Lim HS
Pharmacogenet Genomics; 2015 Dec; 25(12):595-608. PubMed ID: 26367500
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia.
Cacabelos R
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357528
[TBL] [Abstract][Full Text] [Related]
15. Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project.
Pratt VM; Everts RE; Aggarwal P; Beyer BN; Broeckel U; Epstein-Baak R; Hujsak P; Kornreich R; Liao J; Lorier R; Scott SA; Smith CH; Toji LH; Turner A; Kalman LV
J Mol Diagn; 2016 Jan; 18(1):109-23. PubMed ID: 26621101
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics in Alzheimer's disease.
Cacabelos R
Methods Mol Biol; 2008; 448():213-357. PubMed ID: 18370236
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease.
Cacabelos R
Expert Opin Drug Metab Toxicol; 2020 Aug; 16(8):673-701. PubMed ID: 32520597
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy.
Steimer W; Müller B; Leucht S; Kissling W
Clin Chim Acta; 2001 Jun; 308(1-2):33-41. PubMed ID: 11412815
[TBL] [Abstract][Full Text] [Related]
19. Analytical Validation of a Computational Method for Pharmacogenetic Genotyping from Clinical Whole Exome Sequencing.
Ly RC; Shugg T; Ratcliff R; Osei W; Lynnes TC; Pratt VM; Schneider BP; Radovich M; Bray SM; Salisbury BA; Parikh B; Sahinalp SC; Numanagić I; Skaar TC
J Mol Diagn; 2022 Jun; 24(6):576-585. PubMed ID: 35452844
[TBL] [Abstract][Full Text] [Related]
20. Dill Shows Potential for Herb-Drug Interactions via Up-Regulation of
Udomsak W; Chatuphonprasert W; Jarukamjorn K
Pak J Biol Sci; 2022 Jan; 25(1):56-66. PubMed ID: 35001576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
